老药新用在乳腺癌治疗中的研究进展

doi:10.3969/j.issn.1674-8115.2024.11.013

上海交通大学学报（医学版） ›› 2024, Vol. 44 ›› Issue (11): 1454-1459.doi: 10.3969/j.issn.1674-8115.2024.11.013

• 综述 • 上一篇

老药新用在乳腺癌治疗中的研究进展

谭辰¹(), 徐张润², 薛阳³, 陈佳钰⁴, 姚力郡⁵()

^1.上海交通大学医学院附属第六人民医院骨科，上海 200030
^2.上海交通大学医学院分子生物学实验室，上海 200025
^3.上海交通大学医学院附属第六人民医院检验科，上海 200030
^4.上海交通大学医学院附属第九人民医院心内科，上海 200011
^5.上海交通大学医学院附属第六人民医院内分泌代谢科，上海 200030

收稿日期:2024-02-21 接受日期:2024-06-14 出版日期:2024-11-28 发布日期:2024-11-28
通讯作者: 姚力郡 E-mail:tan_chen@sjtu.edu.cn;audreyyao@sjtu.edu.cn
作者简介:谭　辰（2001—），男，硕士生；电子信箱：tan_chen@sjtu.edu.cn。
基金资助:
国家自然科学基金(82272645)

Research progress in drug repurposing in the treatment of breast cancer

TAN Chen¹(), XU Zhangrun², XUE Yang³, CHEN Jiayu⁴, YAO Lijun⁵()

^1.Department of Orthopedics, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
^2.Laboratory of Molecular Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
^3.Department of Clinical Laboratory, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
^4.Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
^5.Department of Endocrinology and Metabolism, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China

Received:2024-02-21 Accepted:2024-06-14 Online:2024-11-28 Published:2024-11-28
Contact: YAO Lijun E-mail:tan_chen@sjtu.edu.cn;audreyyao@sjtu.edu.cn
Supported by:
National Natural Science Foundation of China(82272645)

摘要/Abstract

摘要：

乳腺癌作为全球女性发病率最高的癌症，给世界女性健康造成了巨大负担。现有的治疗方法成本高昂且伴有耐药的风险。老药新用作为一种效益高且省时的药物研究策略，越来越受到研究者们的关注。许多已经用于临床或正在进行临床试验的药物，可用于新的临床适应证。基于对药物作用机制和乳腺癌病理生理过程的深入了解，研究者们可以更好地聚焦具备抗乳腺癌潜力的药物并将其转化到临床实践中。该文综述了目前与乳腺癌治疗相关的老药新用的研究，归纳总结这些药物的作用机制，探讨老药新用策略面临的挑战。

关键词: 老药新用, 乳腺癌, 化学治疗, 抗肿瘤

Abstract:

Breast cancer has become one of the most prevalent cancers among women worldwide, posing a significant burden on their health. Current standard therapies are often expensive and associated with the risk of drug resistance. Drug repurposing has gained increasing attention as a cost-effective and time-saving strategy in pharmaceutical research. Many drugs already in clinical use or undergoing clinical trials can be repurposed for the treatment of new clinical indications. Based on a comprehensive understanding of the mechanisms of action of these drugs and the pathophysiological processes of breast cancer, researchers can better identify drugs with potential anti-breast cancer properties and translate them into clinical practice. This paper provides a review of the current research on repurposing existing drugs for breast cancer treatment, summarizes the mechanisms of action of these drugs, and discusses the challenges associated with the strategy of drug repurposing.

Key words: drug repurposing, breast cancer, chemotherapy, anti-tumor

中图分类号:

R730.5

谭辰, 徐张润, 薛阳, 陈佳钰, 姚力郡. 老药新用在乳腺癌治疗中的研究进展[J]. 上海交通大学学报（医学版）, 2024, 44(11): 1454-1459.

TAN Chen, XU Zhangrun, XUE Yang, CHEN Jiayu, YAO Lijun. Research progress in drug repurposing in the treatment of breast cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(11): 1454-1459.

参考文献 49

1	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
2	FISUSI F A, AKALA E O. Drug combinations in breast cancer therapy[J]. Pharm Nanotechnol, 2019, 7(1): 3-23.
3	SCHIPPER L J, ZEVERIJN L J, GARNETT M J, et al. Can drug repurposing accelerate precision oncology?[J]. Cancer Discov, 2022, 12(7): 1634-1641.
4	XIA Y, SUN M, HUANG H, et al. Drug repurposing for cancer therapy[J]. Signal Transduct Target Ther, 2024, 9: 92.
5	REN J, WANG B, WU Q, et al. Combination of niclosamide and current therapies to overcome resistance for cancer: new frontiers for an old drug[J]. Biomed Pharmacother, 2022, 155: 113789.
6	GYAMFI J, LEE Y H, MIN B S, et al. Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis[J]. Sci Rep, 2019, 9: 11336.
7	KIM J H, PARK S, JUNG E, et al. A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis[J]. Proc Natl Acad Sci USA, 2023, 120(21): e2304081120.
8	SANSONE P, STORCI G, TAVOLARI S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland[J]. J Clin Invest, 2007, 117(12): 3988-4002.
9	ASGEIRSSON K S, OLAFSDÓTTIR K, JÓNASSON J G, et al. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer[J]. Cytokine, 1998, 10(9): 720-728.
10	KORKAYA H, KIM G I, DAVIS A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2⁺ breast cancer by expanding the cancer stem cell population[J]. Mol Cell, 2012, 47(4): 570-584.
11	LIU H, YAN R, XIAO Z, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling[J]. Breast Cancer Res, 2023, 25(1): 43.
12	TERRY M B, GAMMON M D, ZHANG F F, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk[J]. JAMA, 2004, 291(20): 2433-2440.
13	LØFLING L, STØER N C, NAFISI S, et al. Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women[J]. Eur J Epidemiol, 2023, 38(4): 413-426.
14	LI W, ZHANG Z, WANG B, et al. MicroRNA and cyclooxygenase-2 in breast cancer[J]. Clin Chim Acta, 2021, 522: 36-44.
15	LI J, HAO Q, CAO W, et al. Celecoxib in breast cancer prevention and therapy[J]. Cancer Manag Res, 2018, 10: 4653-4667.
16	BOWERS L W, MAXIMO I X, BRENNER A J, et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions[J]. Cancer Res, 2014, 74(16): 4446-4457.
17	HAMY A S, TURY S, WANG X, et al. Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by COX-2 expression and ER status: exploratory analysis of the REMAGUS02 trial[J]. J Clin Oncol, 2019, 37(8): 624-635.
18	MATTHEWS H K, BERTOLI C, DE BRUIN R A M. Cell cycle control in cancer[J]. Nat Rev Mol Cell Biol, 2022, 23: 74-88.
19	HIGHLEY M S, LANDUYT B, PRENEN H, et al. The nitrogen mustards[J]. Pharmacol Rev, 2022, 74(3): 552-599.
20	WAKS A G, WINER E P. Breast cancer treatment: a review[J]. JAMA, 2019, 321(3): 288-300.
21	SHI K, WANG G, PEI J, et al. Emerging strategies to overcome resistance to third-generation EGFR inhibitors[J]. J Hematol Oncol, 2022, 15(1): 94.
22	LI C L, FANG Z X, WU Z, et al. Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy[J]. Biomed Pharmacother, 2022, 154: 113616.
23	JIN M, ZENG B, LIU Y, et al. Co-delivery of repurposing itraconazole and VEGF siRNA by composite nanoparticulate system for collaborative anti-angiogenesis and anti-tumor efficacy against breast cancer[J]. Pharmaceutics, 2022, 14(7): 1369.
24	KHAN S, SHUKLA S, FARHAN M, et al. Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis[J]. Life Sci, 2020, 256: 117976.
25	GÖBEL A, RAUNER M, HOFBAUER L C, et al. Cholesterol and beyond: the role of the mevalonate pathway in cancer biology[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188351.
26	JIANG W, HU J W, HE X R, et al. Statins: a repurposed drug to fight cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 241.
27	BAI F, YU Z, GAO X, et al. Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p[J]. Aging (Albany NY), 2019, 11(10): 3198-3219.
28	YULIAN E D, SIREGAR N C, BAJUADJI. Combination of simvastatin and FAC improves response to neoadjuvant chemotherapy in locally advanced breast cancer[J]. Cancer Res Treat, 2021, 53(4): 1072-1083.
29	FELDT M, BJARNADOTTIR O, KIMBUNG S, et al. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial[J]. J Transl Med, 2015, 13: 133.
30	YU M, LI R, ZHANG J. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer[J]. Biochem Biophys Res Commun, 2016, 471(4): 639-645.
31	NIKAS I P, PASCHOU S A, RYU H S. The role of nicotinamide in cancer chemoprevention and therapy[J]. Biomolecules, 2020, 10(3): E477.
32	JUNG M, LEE K M, IM Y, et al. Nicotinamide (niacin) supplement increases lipid metabolism and ROS-induced energy disruption in triple-negative breast cancer: potential for drug repositioning as an anti-tumor agent[J]. Mol Oncol, 2022, 16(9): 1795-1815.
33	EVANS J M, DONNELLY L A, EMSLIE-SMITH A M, et al. Metformin and reduced risk of cancer in diabetic patients[J]. BMJ, 2005, 330(7503): 1304-1305.
34	HUA Y, ZHENG Y, YAO Y, et al. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing[J]. J Transl Med, 2023, 21(1): 403.
35	AMARAL I, SILVA C, CORREIA-BRANCO A, et al. Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells[J]. Biomed Pharmacother, 2018, 102: 94-101.
36	MAHMOUDI G, EHTESHAMINIA Y, KOKHAEI P, et al. Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines[J]. Cell Commun Signal, 2024, 22(1): 10.
37	ZANNELLA V E, DAL PRA A, MUADDI H, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response[J]. Clin Cancer Res, 2013, 19(24): 6741-6750.
38	MADAK J T, BANKHEAD A, CUTHBERTSON C R, et al. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer[J]. Pharmacol Ther, 2019, 195: 111-131.
39	BROWN K K, SPINELLI J B, ASARA J M, et al. Adaptive reprogramming of De novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer[J]. Cancer Discov, 2017, 7(4): 391-399.
40	LU C, LI X Y, REN Y Y, et al. Disulfiram: a novel repurposed drug for cancer therapy[J]. Cancer Chemother Pharmacol, 2021, 87(2): 159-172.
41	SKROTT Z, MISTRIK M, ANDERSEN K K, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4[J]. Nature, 2017, 552: 194-199.
42	LIU C, QIANG J, DENG Q, et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression[J]. Cancer Res, 2021, 81(23): 5919-5934.
43	HOPKINS J L, LAN L, ZOU L. DNA repair defects in cancer and therapeutic opportunities[J]. Genes Dev, 2022, 36(5/6): 278-293.
44	KIM D, NAM H J. PARP inhibitors: clinical limitations and recent attempts to overcome them[J]. Int J Mol Sci, 2022, 23(15): 8412.
45	ZHU H, WEI M, XU J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications[J]. Mol Cancer, 2020, 19(1): 49.
46	ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6): 523-533.
47	LITTON J K, RUGO H S, ETTL J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8): 753-763.
48	XIA C, DONG X, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
49	MORELLO L. More cuts loom for US science[J]. Nature, 2013, 501: 147-148.

[1]	马美丽, 滕家俊, 高志强, 施春雷, 钟华, 韩宝惠. 原发性纵隔卵黄囊瘤临床和影像学分析[J]. 上海交通大学学报（医学版）, 2024, 44(9): 1155-1161.
[2]	吴其蓁, 刘启明, 柴烨子, 陶政宇, 王依楠, 郭欣宁, 姜萌, 卜军. 机器学习预测乳腺癌新辅助治疗后炎症代谢状态改变的模型评价[J]. 上海交通大学学报（医学版）, 2024, 44(9): 1169-1181.
[3]	韩依杉, 徐梓淇, 陶梦玉, 范广建, 余波. PRMT6促进乳腺癌细胞的增殖和迁移[J]. 上海交通大学学报（医学版）, 2024, 44(8): 999-1010.
[4]	杜少倩, 陶梦玉, 曹源, 王红霞, 胡孝渠, 范广建, 臧丽娟. CXCL9在乳腺癌中的表达及其与肿瘤免疫浸润特征的相关性研究[J]. 上海交通大学学报（医学版）, 2023, 43(7): 860-872.
[5]	王洁仪, 郑丹, 郑晓皎, 贾伟, 赵爱华. 茶褐素生物学活性及其作用机制的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(6): 768-774.
[6]	梅艳青, 韩雨洁, 翁文筠, 张蕾, 唐玉杰. 靶向抑制CDK12/13在高级别胶质瘤中的体外治疗效果和作用分子机制探究[J]. 上海交通大学学报（医学版）, 2023, 43(5): 545-559.
[7]	曹源, 王红霞, 朱灜, 李军建. 四次跨膜蛋白1在乳腺癌中的表达及其促进乳腺癌进展的作用机制[J]. 上海交通大学学报（医学版）, 2023, 43(3): 293-300.
[8]	杨笑萱, 朱珊, 钱程, 储晓英. 术中使用小剂量右美托咪定对乳腺癌手术患者预后的影响[J]. 上海交通大学学报（医学版）, 2023, 43(2): 194-200.
[9]	王斓茜, 马官荣, 姜咏竹, 常秀林, 方廖琼, 白晋. 大肠埃希菌外膜囊泡对乳腺癌细胞增殖及荷瘤小鼠肿瘤生长的影响[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1245-1254.
[10]	汤开然, 吴琼, 黄思佳, 邱旭东, 李文彦, 邓华云, 黄雷. 与MUC1共同调控肿瘤化疗耐药的MUCIN家族成员的筛选[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1288-1295.
[11]	金磊, 徐文彬, 叶晨静, 阎骅. 泊沙康唑对血液恶性肿瘤化疗患者的预防性抗真菌作用[J]. 上海交通大学学报（医学版）, 2022, 42(6): 792-796.
[12]	夏坤健, 邓林林, 王琳. 乳腺癌化学治疗致肝损伤预测模型的构建及其评价[J]. 上海交通大学学报（医学版）, 2022, 42(4): 502-509.
[13]	林艳艳, 许岩, 李慧. 儿童急性淋巴细胞白血病化学治疗常规药物耐药机制的研究进展[J]. 上海交通大学学报(医学版), 2022, 42(2): 211-217.
[14]	张郁瑭, 金奕婕, 张凤春, 徐迎春. 乳腺癌合并新型冠状病毒肺炎感染患者的抗肿瘤合理化诊疗方案探讨[J]. 上海交通大学学报（医学版）, 2022, 42(12): 1745-1750.
[15]	苏俊澄, 王禹铮, 唐雷, 徐迎春, 张凤春. 乳腺癌脑转移患者的临床病理特征及预后的影响因素分析[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1562-1568.

老药新用在乳腺癌治疗中的研究进展

Research progress in drug repurposing in the treatment of breast cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

编辑推荐

Metrics